GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer

Inclusion Criteria: 1. Have provided written and signed informed consent; 2. Histologically confirmed invasive ductal carcinoma; 3. Planned to received (neo)/adjuvant chemotherapy; 4. Eastern Cooperative Oncology Group (ECOG) score of 0 to 1; 5. Can cope with HVLT-RDR and ADAS-Cog evaluation; 6. No prior therapy could induce neurological damage,within 4 weeks 7. Normal blood routine, liver and kidney functions within 1 week before enrollment in this study; 8. Women of childbearing age have a negative serum or urinary pregnancy tests prior to enrollment in this study; Pre-menopause women are contracepted with medically acceptable methods during the study period. 9. Compliance with the study protocol. Exclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) score ≥ 2; 2. Hypersensitivity to experiment agents or components; 3. Women with pregnancy or breast feeding; 4. A clear past history of neurological or psychiatric disorders, including epilepsy or dementia; 5. Abnormal baseline impairment of cognitive impairment; 6. Poor compliance, unwillingness or inability to follow protocol to continue the study; 7. Any circumstances in which the investigator deemed the subject unsuitable for enrollment in this study.